Table 4.
Comparison of adjusted demographic and baseline clinical characteristics of patients from the international observational studies (RIVER and XANTUS), studies from Japan (EXPAND and XAPASS)
| RIVER | XANTUS | EXPAND | XAPASS | |
|---|---|---|---|---|
| Patients, n | 5072 | 6784 | 7141 | 11,308 |
| Patient characteristics | ||||
| Sex, male (%) | 55.7 | 59.2 | 67.7 | 61.9 |
| Age, mean (SD) | 69.5 (11.0) | 71.5 (10.0) | 71.6 (9.4) | 73.1 (9.9) |
| BMI (Kg/m2), mean (SD) | 29.2 (5.7) | 28.3 (5.0) | NA | 23.7 (3.8) |
| Creatinine clearance (mL/min), mean (SD) | 83.7 (35.6) | NA | 69.7 (26.2) | 67.7 (28.9) |
| < 15 mL/min (%) | 0.02 | 0.3 | NA | 0.03 |
| ≥ 15 to < 30 mL/min (%) | 0.7 | 1.1 | 1.9 | 2.8 |
| ≥ 30 to < 50 mL/min (%) | 7.9 | 8.0 | 18.9 | 21.1 |
| ≥ 50 mL/min (%) | 53.4 | 56.2 | 74.6 | 68.0 |
| Missing (%) | 38.0 | 34.4 | 4.7 | 8.2 |
| Rivaroxaban dose/dosing frequency | ||||
| 10 mg once daily | 105 (2.1) | NA | NA | NA |
| 15 mg once daily | 1008 (20.0) | 1410 (20.8) | NA | NA |
| 20 mg once daily | 3867 (76.5) | 5336 (78.7) | NA | NA |
| 10 mg twice daily | 10 (0.2) | NA | NA | NA |
| 15 mg twice daily | 29 (0.6) | NA | NA | NA |
| 20 mg twice daily | 22 (0.4) | NA | NA | NA |
| 10/15/20 mg other dosing Regimen | 12 (0.2) | 35 (0.5) | NA | NA |
| CHADS2 score, mean (SD) | 1.9 (1.2) | 2.0 (1.3) | 2.1 (1.3) | 2.2 (1.3) |
| CHA2DS2-VASc score, mean (SD) | 3.2 (1.6) | 3.4 (1.7) | 3.4 (1.7) | NA |
| Comorbidity/medical history | ||||
| Congestive heart failure (%) | 21.5 | 18.6 | 26.1 | 25.0 |
| Hypertension (%) | 77.0 | 74.7 | 70.9 | 74.3 |
| Diabetes mellitus (%) | 24.3 | 19.6 | 24.3 | 22.3 |
| History of stroke/systemic embolism/TIA (%) | 13.4 | 19.0 | 24.1 | 23.7 |
| Type of AF | ||||
| Paroxysmal (%) | 34.2 | 40.7 | 44.8 | NA |
| Non-paroxysmal (persistent/permanent) (%) | 31.6 | 40.8 | 55.2 | NA |
| First diagnosed (%) | 34.2 | 18.5 | NA | NA |